Business Wire

ERYTECH to Present Results from Phase I Trial of eryaspase in ALL and New Pre-clinical Data at AACR 2018

Jaa

Regulatory News:

ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present full results from its U.S. Phase I trial evaluating eryaspase (GRASPA ® ) in combination with chemotherapy for the treatment of acute lymphoblastic leukemia (ALL) and pre-clinical data on the erymethionase program at the upcoming American Association for Cancer Research Annual Meeting, being held April 14-18, 2018 in Chicago, Illinois.

The U.S. Phase I ALL data will be presented during the poster session of the Phase I clinical trials by the lead author of the abstract, Dr. Alison Walker. The data from the dose-escalating Phase I clinical study demonstrate that eryaspase, L-asparaginase encapsulated in red blood cells, was well-tolerated when combined with CALGB 8811 protocol for frontline treatment of adults with ALL. Based on the PK data and the safety findings, the recommended dose for further clinical development is determined at 100 U/kg.

ERYTECH will also present pre-clinical data on the combination of eryaspase and erymethionase, methionine-gamma-lyase encapsulated in red blood cells, at a poster session on Wednesday, April 18, which show promising in vitro and in vivo bi-therapy therapeutic efficacy in different cancer models.

Poster Session: A Phase I study of eryaspase (L-asparaginase encapsulated in red blood cells) in combination with induction and consolidation chemotherapy for adult patients with newly diagnosed acute lymphoblastic leukemia (ALL)

Poster:

    #CT023 / 16

Lead Author:

Dr. Alison Walker

Poster Session/Section:

PO.CT01 - Phase I Clinical Trials 1

Date:

Sunday, April 15

Time:

1:00 p.m. – 5:00 p.m.
 
 

Poster Session: Enzymatic combination investigation in cancer therapy

 

Poster:

#5827 / 23

Lead Author:

Karine Aguera

Poster Session/Section:

PO.ET01.04 - Combination Chemotherapy 2

Date:

Wednesday, April 18

Time:

8:00 AM – 12:00 PM
 

Abstracts are available on the AACR website. The two posters are to be presented at the 2018 AACR Annual Meeting and will be available on the Erytech website after April 18, 2018.

About ERYTECH and eryaspase (GRASPA®): www.erytech.com

Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH’s initial focus is on the development of products that target the altered amino acid metabolism of cancer cells, depriving them of nutrients necessary for their survival.

The Company’s lead product, eryaspase, also known under the trade name GRASPA®, consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells. L-asparaginase has been a standard component of multi-agent chemotherapy for the treatment of pediatric acute lymphoblastic leukemia (ALL), but side effects limit treatment compliance, especially in adults and patients with weak performance status.

Eryaspase demonstrated positive efficacy and safety results in various clinical trials in ALL, including in a Phase 2 study in patients over 55 years of age and in a Phase 2/3 trial in relapsed or refractory ALL patients, as well as in pancreatic cancer, where it achieved positive results in a Phase 2b trial of second-line treatment of patients with metastatic pancreatic cancer. ERYTECH is preparing for the launch of a pivotal Phase 3 clinical trial in second line pancreatic cancer and Phase 2 trials in first line pancreatic cancer and triple-negative breast cancer.

ERYTECH produces eryaspase at its own GMP-approved and operational manufacturing site in Lyon (France), and at a site for clinical production in Philadelphia (USA). ERYTECH has entered into licensing and distribution partnership agreements for eryaspase for ALL and AML in Europe with Orphan Europe (Recordati Group), and for ALL in Israel with TEVA, which will market the product under the GRASPA® brand name. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designations for eryaspase for the treatment of ALL, AML and pancreatic cancer.

In addition to eryaspase, ERYTECH is developing erymethionase, methionine-γ-lyase encapsulated in red blood cells, to target cancer cells’ amino acid metabolism and induce tumor starvation. ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme replacement therapies (ERYZYME).

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

Forward-looking information

This press release contains forward-looking statements, forecasts and estimates with respect to the clinical results from and the development plans of eryaspase, business and regulatory strategy, and anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH's control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Further description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers, the Company’s Securities and Exchange Commission filings and reports, including in the Company’s prospectus filed pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, on November 13, 2017 and future filings and reports by the Company. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law.

Contact information

ERYTECH
Naomi Eichenbaum
Director of Investor Relations
+33 4 78 74 44 38
+1 917 312 5151
naomi.eichenbaum@erytech.com
or
NewCap
Julien Perez
Investor relations
Nicolas Merigeau
Media relations
+33 1 44 71 98 52
erytech@newcap.eu

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

New Industry Research Shows Augmented Reality Adopters Have Best-in-Class Performance Related to Factory Operations, Service, and Training18.10.2018 13:00Tiedote

PTC (NASDAQ: PTC) today announced from Augmented World Expo (AWE) Europe 2018 the availability of new research in conjunction with Aberdeen Group titled, “How the Best-in-Class Use Augmented Reality for Superior Service Management.” The comprehensive research study and corresponding report identifies significant financial improvements realized by industrial companies embracing augmented reality (AR), and provides best practices for unlocking the potential of the technology across various environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181018005051/en/ PTC announced exclusive data from Aberdeen Group shows that organizations using augmented reality have experienced significant year-over-year business growth and have improved their bottom lines dramatically. (Graphic: Business Wire). In addition to the report published today, PTC announced exclusive data from Aberdeen that shows that organizations using AR have ex

PotNetwork Holdings, Inc. Concludes Record Breaking 3rd Quarter with Revenues Exceeding $6.1 Million18.10.2018 13:00Tiedote

PotNetwork Holdings, Inc. (OTC Pink: POTN ) today announced third quarter revenues totaling $6.1 Million representing a 37% increase over the same period last year. The Company committed to increasing marketing during the last year resulting in the increase of year over year revenue. The marketing budget increased by more than 200% during that time. Diamond CBD distributes premium quality products and has established a successful, continually broadening distribution footprint. Diamond CBD’s products are taking advantage of the popularity of hemp-derived CBD. Diamond’s hemp-derived CBD products do not contain any THC and are tested for purity. Driven by the continually growing results of its wholly-owned subsidiary, Diamond CBD, Inc., PotNetwork Holdings, Inc. has recently filed its Form 10 registration statement with the U.S. Securities and Exchange Commission that includes the Company’s audited financial statements. Additionally, PotNetwork Holdings, Inc. intends to seek listing on th

Cigalah Medpharm Announces the Launch in Saudi Arabia and United Arab Emirates of Nexodyn® AOS, the Tehclo-Based Wound Cleanser Developed by the Swiss Pharma Company APR18.10.2018 12:30Tiedote

Nexodyn® AcidOxidizing Solution (AOS), the Tehclo-based cleanser for acute and chronic wound management, is now starting to be available in Saudi Arabia and United Arab Emirates (UAE), promoted and commercialized by the leading pharmaceutical company Cigalah Medpharm, part of Cigalah Group, following an exclusive partnership with the Swiss Pharma company APR Applied Pharma Research (“APR”). The current size of wound care market in Saudi Arabia and United Arab Emirates accounts for almost 70 million USD and it’s expected to keep growing in the next years because of the aging of the population and the increasing prevalence of chronic wounds, which represent roughly the 70% of the total market. As confirmed by market research, strong is the need from Healthcare Professionals (HCP) of new treatment options to ensure a faster and effective wound healing. The innovative wound cleanser, Nexodyn® AOS, based on APR’s proprietary and patented technology Tehclo®, offers to HCPs and caregivers a n

New Open Applications Advance Comprehensive Modeling Environment for Multidiscipline Collaboration18.10.2018 11:58Tiedote

The Year in Infrastructure 2018 Conference – Bentley Systems, Incorporated, the leading global provider of comprehensive software solutions for advancing the design, construction, and operations of infrastructure, today launched OpenSite Designer, a built-for-purpose application for the design and construction of civil site projects. It also launched OpenBuildings, bringing together its AECOsim building design and Speedikon factory and industrial design applications; and announced the availability of OpenBuildings Station Designer, a specialized application for designing rail and metro stations. At the same time, Bentley announced the availability of OpenBridge Designer, which combines Bentley’s bridge modeling, analysis and design capabilities into one comprehensive package, and OpenFlows FLOOD, a flood analysis and early warning system. In addition, in pursuit of its ‘industrialization’ strategy, Bentley announced it has rebranded under its Open portfolio several of its applications

Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc18.10.2018 10:19Tiedote

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (“Takeda”) announces that it has received unconditional clearance from the Japan Fair Trade Commission for the proposed acquisition of Shire plc announced on May 8, 2018 (the “Acquisition”). The receipt of antitrust clearance in Japan is another significant step towards closing the transaction. In addition to Japan, the Acquisition has now received unconditional clearances from regulatory authorities in multiple key jurisdictions, including the United States, China and Brazil, among others. “We are very pleased to have received unconditional clearance from the Japan Fair Trade Commission for our proposed acquisition of Shire,” said Christophe Weber, President and Chief Executive Officer of Takeda. “Takeda is proud of its Japanese heritage, and we are look

FedEx Expanding Freight Forwarding Capabilities with Acquisition of Manton18.10.2018 09:00Tiedote

FedEx Corp. (NYSE:FDX) announced today that it has agreed to acquire Manton Air-Sea Pty Ltd, a leading provider of logistics services, including freight forwarding and customs brokerage solutions. Manton’s capabilities complement and expand the FedEx portfolio of offerings essential to the rapidly growing global commerce landscape. The acquisition is expected to close later this year and is subject to customary closing conditions. With operations across Australia, Manton connects customers to global markets through regional gateways and relationships with multiple air carriers. With specific expertise in the healthcare and automotive markets, Manton is a proven leader in air and ocean freight forwarding solutions, as well as customs brokerage. Headquartered in Sydney, Australia, Manton will operate as a subsidiary of the FedEx Trade Networks operating company. “Adding Manton’s capabilities to FedEx Trade Networks and the broader FedEx portfolio will open up opportunities for us to cont

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme